2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-33914R
    4-Hydroxymethylpyrazole (Standard) 25222-43-9 98%
    4-Hydroxymethylpyrazole (Standard) is an analytical standard for 4-Hydroxymethylpyrazole (HY-33914). This product is intended for research and analytical applications. 4-Hydroxymethylpyrazole is the primary metabolite of fomepizole (HY-B0876) via hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole inhibits alcohol dehydrogenase (ADH) in humans and monkeys, but the inhibition constant is much higher than that of fomepizole and is therefore negligible in vivo
    4-Hydroxymethylpyrazole (Standard)
  • HY-42680A
    Tagatose 17598-81-1 98%
    Tagatose is a low-calorie sugar substitute. Tagatose exhibits beneficial effects on postprandial hyperglycaemia and hyperinsulinaemia. Tagatose can induce weight loss and raise high-density lipoprotein cholesterol. Tagatose has antioxidant activity. Tagatose can be studied in research on type 2 diabetes and obesity.
    Tagatose
  • HY-42680S
    D-Tagatose-13C 478506-42-2 99.66%
    D-Tagatose-13C is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose-13C
  • HY-43470R
    3α,12β-Dihydroxycholanoic acid (Standard) 570-62-7
    3α,12β-Dihydroxycholanoic acid (Standard) is the analytical standard of 3α,12β-Dihydroxycholanoic acid. This product is intended for research and analytical applications. 3α,12β-Dihydroxycholanoic acid is a bile acid that can be isolated from urine specimens of healthy humans[1].
    3α,12β-Dihydroxycholanoic acid (Standard)
  • HY-43948R
    Hexyl methanesulfonate (Standard) 16156-50-6
    Hexyl methanesulfonate (Standard) is the analytical standard of Hexyl methanesulfonate. This product is intended for research and analytical applications. Hexyl methanesulfonate (Methanesulfonic acid hexyl ester) is an ester product.
    Hexyl methanesulfonate (Standard)
  • HY-50919R
    Paricalcitol (Standard) 131918-61-1
    Paricalcitol (Standard) is the analytical standard of Paricalcitol. This product is intended for research and analytical applications. Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
    Paricalcitol (Standard)
  • HY-75087R
    (R)-pyrrolidine-2-carboxylic acid (Standard) 344-25-2
    (R)-pyrrolidine-2-carboxylic acid (Standard) is the analytical standard of (R)-pyrrolidine-2-carboxylic acid. This product is intended for research and analytical applications. (R)-pyrrolidine-2-carboxylic acid ((+)-(R)-Proline) is a proline isomer that exhibits high renal and hepatotoxicity in rats. (R)-pyrrolidine-2-carboxylic acid can be used to study amino acid metabolism and toxicity mechanisms[1].
    (R)-pyrrolidine-2-carboxylic acid (Standard)
  • HY-75087S
    (R)-Pyrrolidine-2-carboxylic acid-d3 1994265-09-6 98%
    (R)-Pyrrolidine-2-carboxylic acid-d3 is the deuterium labeled (R)-pyrrolidine-2-carboxylic acid. (R)-pyrrolidine-2-carboxylic acid is an endogenous metabolite.
    (R)-Pyrrolidine-2-carboxylic acid-d3
  • HY-75954S
    2-Hydroxyhexanoic acid-d3 1219798-84-1 98%
    2-Hydroxyhexanoic acid-d3 is the deuterium labeled 2-Hydroxyhexanoic acid (HY-75954). 2-Hydroxyhexanoic acid is an endogenous metabolite.
    2-Hydroxyhexanoic acid-d3
  • HY-76199R
    trans-4-Hydroxycyclohexanecarboxylic acid (Standard) 3685-26-5
    Phenethicillin (sodium) (Standard) is the analytical standard of Phenethicillin (sodium). This product is intended for research and analytical applications. Phenethicillin (α-Phenoxyethylpenicillin) sodium is a Penicillin, and has antimicrobial activity.
    trans-4-Hydroxycyclohexanecarboxylic acid (Standard)
  • HY-76711R
    Naltrexone (Standard) 16590-41-3 98%
    Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone (Standard)
  • HY-77641R
    Cinnamoylglycine (Standard) 16534-24-0
    Cinnamoylglycine (Standard) is the analytical standard of Cinnamoylglycine. This product is intended for research and analytical applications. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment.
    Cinnamoylglycine (Standard)
  • HY-77956R
    Thyminose (Standard) 533-67-5
    Thyminose (Standard) is the analytical standard of Thyminose. This product is intended for research and analytical applications. Thyminose is a natural product, a 2-deoxyaldopentose, that can be obtained by hydrolyzing the nucleosides that make up thym nucleic acid[1].
    Thyminose (Standard)
  • HY-79096S
    BOC-L-Phenylalanine-13C 84771-22-2 98%
    BOC-L-Phenylalanine-13C is a 13C-labeled BOC-L-Phenylalanine (HY-79096). Boc-L-phenylalanine is a Boc-protected L-phenylalanine that can be used in the synthesis of other active compounds. Boc-L-phenylalanine is also a capping agent.
    BOC-L-Phenylalanine-13C
  • HY-79139R
    Pteroic acid (Standard) 119-24-4
    Pteroic acid (Standard) is the analytical standard of Pteroic acid (HY-79139). This product is intended for research and analytical applications. Pteroic acid is a precursor to significant compounds like Folic acid (HY-16637) and Vitamin B12 (HY-B0315). Pteroic acid facilitates the examination of how different compounds influence cell growth and development.
    Pteroic acid (Standard)
  • HY-A0005R
    Clofarabine (Standard) 123318-82-1 98%
    Clofarabine (Standard) is the analytical standard of Clofarabine. This product is intended for research and analytical applications. Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit.
    Clofarabine (Standard)
  • HY-A0012R
    Darifenacin hydrobromide (Standard) 133099-07-7 98%
    Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
    Darifenacin hydrobromide (Standard)
  • HY-A0030R
    Fesoterodine fumarate (Standard) 286930-03-8 98%
    Fesoterodine (fumarate) (Standard) is the analytical standard of Fesoterodine (fumarate). This product is intended for research and analytical applications. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB).
    Fesoterodine fumarate (Standard)
  • HY-A0030S
    Fesoterodine-d7 fumarate 2747918-94-9 98%
    Fesoterodine-d7 (fumarate) is the deuterium labeled Fesoterodine fumarate. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB).
    Fesoterodine-d7 fumarate
  • HY-A0069A
    Doxylamine 469-21-6 99.21%
    Doxylamine is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine is orally active, possessing analgesic and hypnotic activities. Doxylamine enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine can be used for the research of nausea, allergy, insomnia.
    Doxylamine
Cat. No. Product Name / Synonyms Application Reactivity